BioInvent International AB

As of June 30, 2026, BioInvent International AB carries a market capitalization of 147.07M, placing it among publicly traded companies globally. Its enterprise value stands at 118.24M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

BioInvent International AB's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, BioInvent International AB has 65.80M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 7.17, and the price-to-book ratio stands at 5.13.

These figures are as of June 30, 2026. The EV/Sales ratio of 5.76 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 118.24M versus a market cap of 147.07M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, BioInvent International AB maintains a current ratio of 4.06, meaning it holds 4.1x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, BioInvent International AB posted a negative return on equity (ROE) of -60.55, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -51.16, reflecting losses generated across the asset base. The company generates approximately 186,122.87 in revenue per employee across its workforce of 110.25, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, BioInvent International AB recorded 39,904.88 in income tax expense. The company reported a pretax loss of -29.68M and -29.72M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, BioInvent International AB's stock has declined approximately 21.75% over the past 52 weeks. The 50-day moving average sits at 2.06, while the 200-day moving average is 2.23.

Over the twelve months ended June 30, 2026, BioInvent International AB generated 20.52M in revenue and converted that into -29.72M in net income, yielding earnings per share of -0.45. EBITDA reached -29.17M, while operating income came in at -30.88M.

As of June 30, 2026, BioInvent International AB holds 30.77M in cash and equivalents against 1.94M in total debt, resulting in a net debt position of -27.67M. Total book value stands at 28.65M, with working capital of 25.91M providing operational flexibility.

BioInvent International AB produced -24.24M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -355,622.90 in capital expenditures, free cash flow totaled -24.60M - equivalent to -0.37 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -150.51 and net profit margin of -144.81 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -16.73: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.55, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to BioInvent International AB shareholders.

BioInvent International AB's most recent stock split took place on December 14, 2020 with a 25:1 split ratio.